Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Sigyn Therapeutics, Inc. (RGNP)
|
Add to portfolio |
|
|
|
| Price: |
$1.60
| | Metrics |
| OS: |
37.3
|
M
| |
|
|
| Market cap: |
$59.7
|
M
| |
-155
|
% ROIC
|
|
Net debt:
|
$4.92
|
M
| |
|
|
|
EV:
|
$64.6
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($2.3)
|
M
| |
|
|
|
EBIT
|
($2.3)
|
M
| |
|
|
| EPS |
($0.09)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Nov-30-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 1.6 | 3.3 | 0.0 |
| Revenue growth | | -100.0% | 405.6% | -26.2% | | | 7517.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 1.4 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.8 | 1.8 | 0.0 |
| Gross margin | | | 75.1% | 65.7% | 44.2% | 53.8% | 56.1% | 41.5% |
| Sales and marketing | | 0.0 | 0.0 | 0.0 | 0.1 | 0.3 | 0.8 | 0.0 |
| Research and development | 0.7 | 0.4 | | | | | | |
| General and administrative | 1.3 | 0.5 | 0.6 | 0.9 | 1.1 | | | 0.4 |
| EBITA | -2.0 | -0.9 | -0.2 | 0.2 | -1.8 | -0.4 | -0.7 | -0.4 |
| EBITA margin | | | -151.2% | 609.3% | -4699.6% | -28.3% | -21.5% | -898.0% |
| Amortization of intangibles | 0.0 | 0.0 | 0.1 | 0.2 | 0.2 | 0.1 | 0.0 | |
| EBIT | -2.0 | -0.9 | -0.3 | -0.1 | -2.0 | -0.5 | -0.7 | -0.4 |
| EBIT margin | | | -195.1% | -218.6% | -5277.4% | -32.3% | -22.8% | -898.0% |
| Pre-tax income | -3.0 | -1.3 | -3.3 | -2.3 | -3.8 | -0.6 | -0.8 | -0.4 |
| Income taxes | 0.0 | 0.0 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 7.2% | | | 0.0% | 0.0% | 0.0% |
| Earnings from continuing ops | -3.0 | -1.3 | -3.3 | -2.3 | -3.8 | -0.6 | -0.8 | -0.4 |
| Earnings from discontinued ops | | | 0.3 | -0.3 | -0.4 | | | |
| Net income | -3.0 | -1.3 | -3.1 | -2.6 | -4.3 | -0.6 | -0.8 | -0.4 |
| Net margin | | | -2145.3% | -9243.2% | -11061.2% | -40.7% | -24.4% | -898.0% |
| |
| Diluted EPS | ($0.08) | ($0.17) | ($0.04) | ($0.04) | ($0.08) | ($0.06) | ($0.08) | ($0.01) |
| Shares outstanding (diluted) | 36.4 | 7.4 | 81.3 | 65.1 | 47.1 | 10.0 | 9.8 | 28.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|